Evidence map›Paper›PMID 41019764›Full record

ArticleFrontiers in genetics2025

Dissecting and validation the biomarker of heart failure progression in patients with atherosclerosis by single-cell sequencing, bioinformatics, and machine learning.

Lihua Ni, Huabo Li, Juan Du, Ke Zhou, Fugui Zhang, Liankai Wang

Abstract read
In one paragraph

Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lihua Ni *Department of Nephrology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Huabo Li *Department of Cardiology, Minda Hospital of Hubei Minzu University, Enshi, China.
Juan DuDepartment of Cardiology, Minda Hospital of Hubei Minzu University, Enshi, China.
Ke ZhouDepartment of Cardiology, Minda Hospital of Hubei Minzu University, Enshi, China.
Fugui ZhangDepartment of Cardiology, Minda Hospital of Hubei Minzu University, Enshi, China.
Liankai WangDepartment of Cardiology, Minda Hospital of Hubei Minzu University, Enshi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to identify early biomarkers associated with the progression from atherosclerosis (AS) to heart failure (HF) by integrating single-cell RNA sequencing (scRNA-seq) and bulk transcriptomic data, and to explore the potential underlying mechanisms. Method: Transcriptomic datasets (GSE28829 and GSE57345) were obtained from the Gene Expression Omnibus (GEO) database, and single-cell RNA sequencing (scRNA-seq) data were downloaded from the Human Cell Landscape (HCL) platform. Genes of interest were identified by integrating results from weighted gene co-expression network analysis (WGCNA), differentially expressed genes (DEGs) analysis, and cell-type-specific expression patterns. Three machine learning algorithms (LASSO, Random Forest, and SVM-RFE) were employed to screen for robust candidate biomarkers. External validation was performed using three independent datasets: GSE53274, GSE5406, and GSE59867. Result: ScRNA-seq data screened for 2828 cardiac-related genes. WGCNA identified 918 genes highly associated with AS. In addition, the limma package identified 9675 DEGs associated with HF progression. A total of 119 overlapping genes were obtained by intersecting the results from the above three analyses. Based on these 119 overlapping genes, three machine learning algorithms (LASSO, Random Forest, and SVM-RFE) were applied to datasets GSE28829 and GSE57345, and consistently identified CD48 as a robust signature gene, with an area under the curve (AUC) greater than 0.7. External validation confirmed CD48 as a potential biomarker for the progression from AS to HF. Conclusion: CD48 was identified as a potential early biomarker for the transition from AS to HF, which may offer new insights for risk stratification and early intervention in disease progression.

Indexed as

atherosclerosisbioinformaticsHeart failure progressionmachine learningsingle-cell sequencing

Identifiers

PMID41019764
PMCPMC12464422

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.